Online First

August 04, 2020

Correspondence response
Response to: ‘Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew–gender discrepancies at annual EULAR congresses: towards the gap narrowing’ by Conigliaro et al
Free

Kanika Monga, Jean Liew

doi: 10.1136/annrheumdis-2020-218628
Correspondence
Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al
Free

Alessandra Bettiol, Francesca Pregnolato, Savino Sciascia, Giacomo Emmi, Domenico Prisco, Pier Luigi Meroni

doi: 10.1136/annrheumdis-2020-218377
Correspondence
Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al
Free

Maurizio Benucci, Luca Quartuccio, Francesca Li Gobbi, Arianna Damiani, Valentina Grossi, Maria Infantino, Mariangela Manfredi

doi: 10.1136/annrheumdis-2020-218590
Correspondence response
Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial–comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al
Free

Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

doi: 10.1136/annrheumdis-2020-218444
Correspondence
Correspondence to ‘Gender gap in rheumatology: speaker representation at annual conferences’ by Monga and Liew—gender discrepancies at annual EULAR congresses: towards the gap narrowing
Free

Paola Conigliaro, Silvia Laura Bosello, Cristina Iannuccelli, Elisa Gremese, Francesca Romana Spinelli, Marta Vadacca, Maria Sole Chimenti

doi: 10.1136/annrheumdis-2020-218516
Correspondence
Transient monoarthritis and psoriatic skin lesions following COVID-19
Free

Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti

doi: 10.1136/annrheumdis-2020-218520
Correspondence
Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al

Ran Cui, Qian Wang, Hua Zhang, Shan Wu, Xin-Jian Wan, Sheng-Ming Dai

doi: 10.1136/annrheumdis-2020-218546
Correspondence response
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al
Free

Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko

doi: 10.1136/annrheumdis-2020-218686
Correspondence response
Gastrointestinal SLE involvement in SLE classification. Response to: ‘‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al’ by Cui et al
Free

Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson

doi: 10.1136/annrheumdis-2020-218615
Correspondence
Presence of antiphospholipid antibodies in COVID-19: case series study
Free

Luis M Amezcua-Guerra, Gustavo Rojas-Velasco, Malinalli Brianza-Padilla, Armando Vázquez-Rangel, Ricardo Márquez-Velasco, Francisco Baranda-Tovar, Rashidi Springall, Hector Gonzalez-Pacheco, Yaneli Juárez-Vicuña, Claudia Tavera-Alonso, Fausto Sanchez-Muñoz, Marisol Hernández-Salas

doi: 10.1136/annrheumdis-2020-218100
Correspondence response
Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al
Free

Alexis Mathian, Marc Pineton De Chambrun, Alain Combes, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218145

July 31, 2020

Correspondence response
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Free

Pier Leopoldo Capecchi, Pietro Enea Lazzerini

doi: 10.1136/annrheumdis-2020-218627
Correspondence
Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’
Free

Attila Pethoe-Schramm, Jenny Devenport, William Reiss

doi: 10.1136/annrheumdis-2020-218365
Correspondence
COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine
Free

Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun

doi: 10.1136/annrheumdis-2020-218154
Correspondence
More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia
Free

Gianfranco Ferraccioli

doi: 10.1136/annrheumdis-2020-218523
Correspondence response
Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al
Free

Inbal Haya Shafran, Farideh Alasti, Josef S Smolen, Daniel Aletaha

doi: 10.1136/annrheumdis-2020-218403
Correspondence response
Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Free

Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti

doi: 10.1136/annrheumdis-2020-218626
Correspondence
Rational use of tocilizumab in COVID-19
Free

Siddharth Jain, Shefali Khanna Sharma

doi: 10.1136/annrheumdis-2020-218519
Correspondence response
Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218173
Correspondence response
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli
Free

Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna

doi: 10.1136/annrheumdis-2020-218612

July 30, 2020

Letter
The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series
Free

Naomi Serling-Boyd, Amir M Mohareb, Arthur Y Kim, Emily P Hyle, Zachary S Wallace

doi: 10.1136/annrheumdis-2020-218289
Miscellaneous
Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

Svetlana Cherlin, Myles J Lewis, Darren Plant, Nisha Nair, Katriona Goldmann, Evan Tzanis, Michael R Barnes, Paul McKeigue, Jennifer H Barrett, Costantino Pitzalis, Anne Barton, MATURA Consortium, Heather J Cordell

doi: 10.1136/annrheumdis-2020-217204
Correspondence
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al
Free

Ioana Andreica, David Kiefer, Guenther A Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, Xenofon Baraliakos, Juergen Braun

doi: 10.1136/annrheumdis-2020-218609

July 28, 2020

Correspondence
Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?
Free

Akpabio Akpabio, Richard Oluyinka Akintayo, Utibe Effiong

doi: 10.1136/annrheumdis-2020-218449
Correspondence response
Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al
Free

Francesco Caso, Antonio del Puente, Nicolò Girolimetto, Marco Tasso, Corrado Caso, Raffaele Scarpa, Luisa Costa

doi: 10.1136/annrheumdis-2020-218472
Correspondence
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Free

Dennis Scheicht

doi: 10.1136/annrheumdis-2020-217041
Correspondence
External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies
Free

Queenie Luu, Jessica Day, Alix Hall, Vidya Limaye, Gabor Major

doi: 10.1136/annrheumdis-2020-217568

July 24, 2020

Correspondence response
Response to: ‘External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies’ by Luu et al
Free

Masatoshi Jinnin, Akiko Ohta, Hitoshi Kohsaka

doi: 10.1136/annrheumdis-2020-217635
Correspondence
Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia
Free

Sharifah Aishah Wan, Cheng Lay Teh, Benjamin Sachdev Manjit Singh, Yaw Kiet Cheong, Seow Lin Chuah, Ahmad Tirmizi Jobli

doi: 10.1136/annrheumdis-2020-218425
Correspondence
Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’
Free

Xiao-Huan Chen, Chih-Jung Yeh, Han-You Mo, James Cheng Chung Wei

doi: 10.1136/annrheumdis-2020-218451
Correspondence response
Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al
Free

Jixin Zhong, Lingli Dong

doi: 10.1136/annrheumdis-2020-218441
Correspondence response
Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al
Free

Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong

doi: 10.1136/annrheumdis-2020-218508
Correspondence
Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia?

Emine Duran, Levent Kilic, Gamze Durhan, Ahmet Çağkan Inkaya, Gulay Sain Guven, Gul Karakaya, Orhan Macit Ariyurek, Omer Karadag

doi: 10.1136/annrheumdis-2020-218533

July 22, 2020

Correspondence
Microbiome in Sjögren’s syndrome: here we are
Free

Taco A van der Meulen, Arjan Vissink, Hendrika Bootsma, Fred K L Spijkervet, Frans G M Kroese

doi: 10.1136/annrheumdis-2020-218213
Correspondence response
Response to: ‘Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study’ by Goulielmos and Zervou
Free

Fang Xiao Zhu, Jing-Yang Huang, James Cheng-Chung Wei

doi: 10.1136/annrheumdis-2020-218177
Correspondence response
Response to: ‘Microbiome in Sjögren’s syndrome: here we are’ by van der Meulen et al
Free

Julia Manasson, Rebecca B Blank, Jose U Scher

doi: 10.1136/annrheumdis-2020-218327
Correspondence response
Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al
Free

Robert B M Landewé, Hendrik Schulze-Koops

doi: 10.1136/annrheumdis-2020-218470
Correspondence
Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: population-based cohort study
Free

George N Goulielmos, Maria I Zervou

doi: 10.1136/annrheumdis-2020-218128
Correspondence response
Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Moreno et al
Free

Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim

doi: 10.1136/annrheumdis-2020-218432
Crystal arthropathies
Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages

Felix Renaudin, Lucie Orliaguet, Florence Castelli, François Fenaille, Aurelie Prignon, Fawaz Alzaid, Christele Combes, Aurélie Delvaux, Yasmina Adimy, Martine Cohen-Solal, Pascal Richette, Thomas Bardin, Jean-Pierre Riveline, Nicolas Venteclef, Frédéric Lioté, Laure Campillo-Gimenez, Hang-Korng Ea

doi: 10.1136/annrheumdis-2020-217342

July 21, 2020

Correspondence
Comment on: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al
Free

Samet Karahan, Ali Cetinkaya, Kaniye Aydin, Hatice Aslan Sirakaya

doi: 10.1136/annrheumdis-2020-218497
Correspondence
COVID-19 and Behçet’s disease: clinical case series
Free

Gerard Espinosa, Olga Araujo, Sergi Amaro, Marta Bodro, Pedro Juan Moreno, Reinaldo Moreno, Ainoa Ugarte, R Cervera

doi: 10.1136/annrheumdis-2020-217778
Correspondence
COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre
Free

Natasha Cleaton, Sabrina Raizada, Nick Barkham, Srinivasan Venkatachalam, Tom Sheeran, Tochukwu Adizie, Hem Sapkota, Baldev Singh, James Bateman

doi: 10.1136/annrheumdis-2020-218236
IgG4 related disease
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging

Christian Schmidkonz, Simon Rauber, Armin Atzinger, Rahul Agarwal, Theresa Ida Götz, Alina Soare, Michael Cordes, Olaf Prante, Christina Bergmann, Arnd Kleyer, Philipp Ritt, Simone Maschauer, Peter Hennig, Johannes Toms, Markus Köhner, Bernhard Manger, John H Stone, Uwe Haberkorn, Tobias Baeuerle, Jörg H W Distler, Abbas Agaimy, Torsten Kuwert, Georg Schett, Andreas Ramming

doi: 10.1136/annrheumdis-2020-217408
Recommendation
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer

doi: 10.1136/annrheumdis-2020-217209

July 15, 2020

Correspondence response
Response to: ‘Riociguat in systemic sclerosis: a potential for disease modification’ by Jain and Dhir
Free

Dinesh Khanna, Oliver Distler

doi: 10.1136/annrheumdis-2020-218194
Crystal arthropathies
Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study

Hilde Berner Hammer, Lars Karoliussen, Lene Terslev, Espen A Haavardsholm, Tore K Kvien, Till Uhlig

doi: 10.1136/annrheumdis-2020-217392
Correspondence
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India
Free

Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, Akshat Pandey, Nikhil Gupta, Rahul Jain, Shashank Akerkar, Parthajit Das, Rajkiran Dudam, Naval Mendiratta, Bimlesh Dhar Pandey, Mithun CB, Bharat K Singh, Sharath Kumar, Nilesh Nolkha, Shriyanka Jain, Somya Jain, Ashish Sharma, Durga Prasanna Misra

doi: 10.1136/annrheumdis-2020-218013
Correspondence
Riociguat in systemic sclerosis: a potential for disease modification
Free

Siddharth Jain, Varun Dhir

doi: 10.1136/annrheumdis-2020-218180
Correspondence response
Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al
Free

Alexis Mathian, Zahir Amoura

doi: 10.1136/annrheumdis-2020-218146

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online First

August 04, 2020

July 31, 2020

July 30, 2020

July 28, 2020

July 24, 2020

July 22, 2020

July 21, 2020

July 15, 2020

Pages